GLP-1 expands brain role, policy shifts diet, climate

GLP-1s are moving beyond metabolism into mental health, while health policy is finally targeting sugar and climate change at scale.

In today's read: 1. GLP-1s target brain, not just body · 2. Policy wakes up to sugar and climate · 3. Affordability blocks care access · 4. Biotech delivers hyper-specific therapeutics

1. GLP-1s target brain, not just body

GLP-1 agonists now show promise in regulating dopamine pathways and reducing inflammation in the brain. This extends their reach beyond blood sugar control and weight loss, affecting reward systems and mood.

Watch for biotech to heavily invest in neuropsychiatric GLP-1 applications. This expands the market for these drugs far beyond metabolic health, signaling a new frontier in mental health pharmacology.

Evidence from today:

• GLP-1 drugs get trials for depression and addiction — Nature News — Clinical trials are underway for GLP-1 agonists to treat neuropsychiatric conditions like depression, anxiety, and addiction. Researchers are exploring how these drugs, known for regulating appetite and blood sugar, might also affect the brain's reward pathways and inflammation. This could expand their use beyond metabolic health to mental health, potentially reshaping treatment protocols.
• ADA/EASD diabetes guidelines prioritize GLP-1, SGLT2 over metformin — El Médico Interactivo — New guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) for Type 2 diabetes treatment now recommend starting GLP-1 agonists and SGLT2 inhibitors earlier. These drugs are now considered, potentially from diagnosis, rather than making metformin an obligatory first step. It's a big shift in how clinicians approach blood sugar management for millions.
• IBio's GLP-1 combo protects muscle during fat loss in primates — Longevity.Technology — A new study in nonhuman primates found that adding IBIO-610 to semaglutide changed how weight loss happened. With the combo, lean mass made up only 6% of the lost weight, compared to 22% when semaglutide was used alone. The company says fat accounted for 93% of the weight lost with their compound, versus 77% with just semaglutide.

2. Policy wakes up to sugar and climate

Governments are enacting direct policy interventions like sugar taxes and broader calls for climate action. The mechanism is a shift from individual responsibility to systemic regulation to influence public health outcomes via population-wide changes in diet and environment.

Food and beverage companies face revenue hit and reformulation pressure from sugar taxes. Climate policy is becoming a public health mandate, pushing governments to act or face medical community backlash.

Evidence from today:

• Germany moves to tax sugary drinks nationally — Deutsches Ärzteblatt — Germany's federal cabinet just approved a proposal for a national sugar tax on sweetened beverages, especially soft drinks. If passed by parliament, this move will likely make sugary drinks more expensive for consumers. The goal is to improve public health by reducing sugar consumption.
• World Medical Association warns climate change impacts future health — El Médico Interactivo — The World Medical Association (WMA) urged governments to meet climate commitments, citing direct threats to future generations' physical and mental health. This aligns with broader medical community calls for urgent action, linking environmental policy to human physiology and nervous system load.
• Australian health leaders call for urgent climate action ahead of COP31 — Croakey Health Media — Australian health leaders, including the Australian Medical Association and the Public Health Association, issued a joint statement demanding the government commit to the 1.5°C warming limit and phase out fossil fuel subsidies. This follows a Canberra summit focused on climate risks to human health. They're explicitly tying climate policy to population health outcomes, not just environmental impact.
• Scientists warn Bavaria's climate law rollback threatens health — Deutsches Ärzteblatt — German scientists, including physicist Harald Lesch, criticize Bavaria's proposed climate protection law changes as "useless," arguing they fail to protect both the climate and human health. The new draft weakens existing climate goals, with critics stating it will actively harm public health.

3. Affordability blocks care access

High healthcare prices, driven by complex US systems, prevent people from accessing necessary treatments. This inflated cost structure raises insurance premiums and creates a barrier to care, impacting nervous system regulation and overall health outcomes.

This signals ongoing pressure for systemic reform in US healthcare pricing. Companies building solutions that lower access barriers or costs have a market advantage, but the legislative fight will be brutal.

Evidence from today:

• High healthcare prices mean fewer get nervous system care — STAT Health Tech — A STAT Health Tech report highlights how inflated healthcare prices in the US drive up insurance costs, making essential medical care — including mental health and specialized body treatments — less accessible. This isn't just about money; it's about whether people can afford to regulate their nervous system when things go sideways. The series explains how these costs disproportionately affect what treatments and preventative measures are within reach for most.
• Lead in medieval teeth shows unequal health toll — Nature News — New Nature News research, analyzing lead levels in 300 individuals from medieval Germany, found that while lead exposure increased across all social classes during the 13th to 16th centuries due to intensified mining, the poorest residents were disproportionately affected. This suggests a direct link between occupational exposure, socio-economic status, and chronic heavy metal poisoning. It's a clear reminder that environmental toxins impact our body load differently depending on who you are.
• Germany forms commission to reform long-term care system — Deutsches Ärzteblatt — Germany's federal cabinet just appointed a 13-person commission, primarily academics and economists, to overhaul the country's long-term care insurance. They'll work until January 2027 to find a way to fund "appropriate" partial coverage, addressing the financial strain on individuals and the system.

4. Biotech delivers hyper-specific therapeutics

Advances in CRISPR, targeted drug delivery via millirobots, and precision diagnostics allow for treatments that act at a cellular or genetic level. This bypasses systemic side effects and targets disease mechanisms with unprecedented accuracy.

This shifts R&D investment towards highly specific, less invasive interventions. Expect more breakthroughs in cancer and infectious diseases, but also higher development costs and regulatory hurdles for these complex modalities.

Evidence from today:

• Magnetic Millirobots to Deliver Cancer Drugs Directly — Inside Precision Medicine — Researchers are developing tiny magnetic robots to target hard-to-reach tumors in organs like the liver and brain. The goal is to deliver chemotherapy directly to cancer cells, minimizing systemic side effects. Think precision medicine, but with actual mini-submarines.
• CRISPR test 100x more sensitive for HIV, RNA viruses — Inside Precision Medicine — A new CRISPR-Cas13a test can detect RNA viruses like HIV with 100 times greater sensitivity than previous versions, according to a study published in Inside Precision Medicine. This engineering breakthrough means earlier, more accurate detection of viral loads, which matters for managing chronic infections.
• New Drug Option for Non-Muscle Invasive Bladder Cancer — Deutsches Ärzteblatt — A Phase 2 study, TRUCE-04, shows the antibody-drug conjugate Disitamab Vedotin from China can achieve long-term remission in HER2-positive, non-muscle invasive bladder cancer that can't be removed surgically. This offers a new organ-sparing treatment for patients previously out of options.
• Mechanical Pressure Triggers Cancer Cell Death, Halting Metastasis — Inside Precision Medicine — New research found that persistent physical pressure on cancer cells activates a molecular pathway, causing them to die and restricting their movement. This finding could lead to new ways to predict metastatic risk and prevent cancer spread in the body.

Also moved today

• Smartwatch health data swamps doctors, creating new care models — Nature News — Smartwatch data is overwhelming doctors, driving the need for new systems to interpret continuous physiological monitoring in healthcare.
• Telehealth pairs menopause care with mental health — Longevity Technology — Telehealth services combining menopause and mental health care address brain fog and mood swings more effectively than siloed approaches.
• New lab service checks real anti-aging claims for skin — Longevity Technology — A new lab service for skincare allows brands to test anti-aging claims at a cellular level, pushing for more scientific rigor in the beauty industry.
• Atrogi's pill shows early promise for muscle retention in 13 people — Longevity Technology — Atrogi's pill shows early promise for muscle retention alongside fat loss, a critical development for GLP-1 users struggling with sarcopenia.
• Clean Form Nutrition's creatine gets NSF Certified for Sport — Nutritional Outlook — NSF Certified for Sport status for creatine signifies growing demand for clean, verified ingredients in athletic supplements.
• German pharmacists now cleared to give all non-live vaccines — Deutsches Ärzteblatt — Germany expanding pharmacists' ability to administer non-live vaccines improves public access to immunizations and decentralizes healthcare delivery.
• Diet and Exercise Remit Early-Onset Type 2 Diabetes for Half — Deutsches Ärzteblatt — Diet and exercise remit early-onset Type 2 Diabetes for half of patients, suggesting lifestyle changes are a powerful first-line intervention.
• Mepivacaine gel cuts IUD insertion pain, boosting acceptance — Deutsches Ärzteblatt — A new anesthetic gel reduces IUD insertion pain, potentially increasing access to effective contraception by addressing patient discomfort.
• Genetic link for non-smokers' lung cancer found — Deutsches Ärzteblatt — A genetic link to non-smoker lung cancer shifts understanding of risk beyond lifestyle, highlighting the role of inherited factors.
• Fiber and gut health reshape the snack bar market — Nutritional Outlook — The snack bar market is shifting to focus on fiber and gut-friendly ingredients, signaling consumer demand for digestive wellness in convenient formats.

New this week in wellness goods

• Telehealth pairs menopause care with mental health — nationwide US — Better U and Evernow launched a new nationwide telehealth service combining menopause specialists with psychiatry. The service aims to address symptoms like anxiety, sleep issues, and brain fog that often get misdiagnosed as purely mental health concerns. This pairs hormone support directly with psychiatric care for women in perimenopause and menopause.

Signal map

Europe: 19 · North America: 15 · Global: 8 · Nordics: 3 · Oceania: 1

What I'd watch next

I'm watching how the regulatory landscape for AI in medicine evolves at the state level; it determines speed to market. Also, whether any of these GLP-1 brain trials actually deliver on the mental health promise.

Where this fits at Kokorology

The nervous system regulates everything we discussed today. Understanding its load and capacity is why I designed the Nervous System Journal to map daily inputs against your state.